$0.02
(Market cap
$54 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-24 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.1
-
Face value
--
-
Shares outstanding
172,207,008
10 Years Aggregate
CFO
$-108.97 Mln
EBITDA
$-147.95 Mln
Net Profit
$-153.63 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Tyme Technologies (TYME)
| -48.5 | -11.2 | 22.3 | -69.8 | -42.1 | -45.1 | -- |
|
BSE Sensex*
| -10.4 | -1.0 | -7.8 | -7.7 | 6.7 | 8.3 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|
|
Tyme Technologies (TYME)
| -50.6 | -12.9 | -62.1 | -42.0 | 70.1 | -66.7 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Tyme Technologies (TYME)
|
0.3 | 53.5 | 0.0 | -24.2 | -- | -30.1 | -- | 0.7 |
| 76.0 | 3,806.2 | 1.0 | -342.3 | -33,130.6 | -39.2 | -- | 4.8 |
Shareholding Pattern
View DetailsAbout Tyme Technologies (TYME)
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including... pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. As of September 16, 2022, Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc. Read more
-
CEO & Director
Mr. Richard Cunningham
-
CEO & Director
Mr. Richard Cunningham
-
Headquarters
Bedminster, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Tyme Technologies (TYME)
What is the current share price of Tyme Technologies Inc (TYME) Today?
The share price of Tyme Technologies Inc (TYME) is $0.31 (NASDAQ) as of 16-Sep-2022 16:00 EDT. Tyme Technologies Inc (TYME) has given a return of -42.09% in the last 3 years.
What is the current PB & PE ratio of Tyme Technologies Inc (TYME)?
Since, TTM earnings of Tyme Technologies Inc (TYME) is negative, P/E ratio is not available.
The P/B ratio of Tyme Technologies Inc (TYME) is 0.72 times as on 16-Sep-2022, a 86 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-2.55
|
0.75
|
|
2021
|
-8.23
|
2.34
|
|
2020
|
-5.75
|
6.65
|
|
2019
|
-5.44
|
18.57
|
|
2018
|
-10.70
|
7.67
|
What is the 52 Week High and Low of Tyme Technologies Inc (TYME)?
The 52-week high and low of Tyme Technologies Inc (TYME) are Rs -- and Rs -- as of 27-May-2026.
What is the market cap of Tyme Technologies Inc (TYME)?
Tyme Technologies Inc (TYME) has a market capitalisation of $ 54 Mln as on 16-Sep-2022. As per SEBI classification, it is a Small Cap company.
Should I invest in Tyme Technologies Inc (TYME)?
Before investing in Tyme Technologies Inc (TYME), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.